It also allows for the ability to compare the same gene across diseases, contrasting TET2′s favorable prognosis in CMML with its propensity for increased risk of thrombosis in MF, or the involvement of JAK-STAT in MPN with its almost complete absence in aCML. The gene discussed is TET2; the disease is myeloproliferative neoplasm.